Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging

Early diagnosis of disease and follow-up of therapy is of vital importance for appropriate patient management since it allows rapid treatment, thereby reducing mortality and improving health and quality of life with lower expenditure for health care systems. New approaches include nanomedicine-based diagnosis combined with therapy. Nanoparticles (NPs), as contrast agents for in vivo diagnosis, have the advantage of combining several imaging agents that are visible using different modalities, thereby achieving high spatial resolution, high sensitivity, high specificity, morphological, and functional information. In this work, we present the development of aluminum hydroxide nanostructures embedded with polyacrylic acid (PAA) coated iron oxide superparamagnetic nanoparticles, Fe3O4@Al(OH)3, synthesized by a two-step co-precipitation and forced hydrolysis method, their physicochemical characterization and first biomedical studies as dual magnetic resonance imaging (MRI)/positron emission tomography (PET) contrast agents for cell imaging. The so-prepared NPs are size-controlled, with diameters below 250 nm, completely and homogeneously coated with an Al(OH)3 phase over the magnetite cores, superparamagnetic with high saturation magnetization value (Ms = 63 emu/g-Fe3O4), and porous at the surface with a chemical affinity for fluoride ion adsorption. The suitability as MRI and PET contrast agents was tested showing high transversal relaxivity (r2) (83.6 mM−1 s −1 ) and rapid uptake of 18F-labeled fluoride ions as a PET tracer. The loading stability with 18F-fluoride was tested in longitudinal experiments using water, buffer, and cell culture media. Even though the stability of the 18F-label varied, it remained stable under all conditions. A first in vivo experiment indicates the suitability of Fe3O4@Al(OH)3 nanoparticles as a dual contrast agent for sensitive short-term (PET) and high-resolution long-term imaging (MRI).This work was supported by the European Commission under the PANA project, Call H2020-NMP2015-two-stage, Grant 686009, and partially supported by the Consellería de Educación Program for the Development of Strategic Grouping in Materials—AEMAT at the University of Santiago de Compostela under Grant No. ED431E2018/08, Xunta de Galicia, and the Flemish Agency for Innovation by Science and Technology (IWT grant agreement n◦ 140061, SBO ‘NanoCoMIT’). Furthermore, we acknowledge infrastructure funding for the preclinical PET/MRI scanner from ‘Stichting tegen Kanker’ (STK 2015-145) and from the Hercules Stichting (AKUL/13/29). Frederik Cleeren is a Postdoctoral Fellow of The Research Foundation—Flanders (FWO; 12R3119N)S

Characterization of a preclinical PET insert in a 7 tesla MRI scanner: beyond NEMA testing

[EN] This study evaluates the performance of the Bruker positron emission tomograph (PET) insert combined with a BioSpec 70/30 USR magnetic resonance imaging (MRI) scanner using the manufacturer acceptance protocol and the NEMA NU 4-2008 for small animal PET. The PET insert is made of 3 rings of 8 monolithic LYSO crystals (50 x 50 x 10 mm(3)) coupled to silicon photomultipliers (SiPM) arrays, conferring an axial and transaxial FOV of 15 cm and 8 cm. The MRI performance was evaluated with and without the insert for the following radiofrequency noise, magnetic field homogeneity and image quality. For the PET performance, we extended the NEMA protocol featuring system sensitivity, count rates, spatial resolution and image quality to homogeneity and accuracy for quantification using several MRI sequences (RARE, FLASH, EPI and UTE). The PET insert does not show any adverse effect on the MRI performances. The MR field homogeneity is well preserved (Diameter Spherical Volume, for 20 mm of 1.98 +/- 4.78 without and -0.96 +/- 5.16 Hz with the PET insert). The PET insert has no major effect on the radiofrequency field. The signal-to-noise ratio measurements also do not show major differences. Image ghosting is well within the manufacturer specifications (<2.5%) and no RF noise is visible. Maximum sensitivity of the PET insert is 11.0% at the center of the FOV even with simultaneous acquisition of EPI and RARE. PET MLEM resolution is 0.87 mm (FWHM) at 5 mm off-center of the FOV and 0.97 mm at 25 mm radial offset. The peaks for true/noise equivalent count rates are 410/240 and 628/486 kcps for the rat and mouse phantoms, and are reached at 30.34/22.85 and 27.94/22.58 MBq. PET image quality is minimally altered by the different MRI sequences. The Bruker PET insert shows no adverse effect on the MRI performance and demonstrated a high sensitivity, sub-millimeter resolution and good image quality even during simultaneous MRI acquisition.We acknowledge the KU Leuven core facility, Molecular Small Animal Imaging Center (MoSAIC), for their support with obtaining scientific data presented in this paper. This work was supported by Stichting tegen Kanker (2015-145, Christophe M. Deroose) and Hercules foundation (AKUL/13/029, Uwe Himmelreich) for the purchase of the PET and MRI equipment respectively. The work was supported by the following funding organizations: European Commission for the PANA project (H2020-NMP-2015-two-stage, grant 686009) and the European ERA-NET project 'CryptoView' (3rd call of the FP7 program Infect-ERA).Gsell, W.; Molinos, C.; Correcher, C.; Belderbos, S.; Wouters, J.; Junge, S.; Heidenreich, M.... (2020). Characterization of a preclinical PET insert in a 7 tesla MRI scanner: beyond NEMA testing. Physics in Medicine and Biology. 65(24):1-16. https://doi.org/10.1088/1361-6560/aba08cS1166524Balezeau, F., Eliat, P.-A., Cayamo, A. B., & Saint-Jalmes, H. (2011). Mapping of low flip angles in magnetic resonance. Physics in Medicine and Biology, 56(20), 6635-6647. doi:10.1088/0031-9155/56/20/008Benlloch, J. M., González, A. J., Pani, R., Preziosi, E., Jackson, C., Murphy, J., … Schwaiger, M. (2018). The MINDVIEW project: First results. European Psychiatry, 50, 21-27. doi:10.1016/j.eurpsy.2018.01.002Cal-Gonzalez, J., Rausch, I., Shiyam Sundar, L. K., Lassen, M. L., Muzik, O., Moser, E., … Beyer, T. (2018). Hybrid Imaging: Instrumentation and Data Processing. Frontiers in Physics, 6. doi:10.3389/fphy.2018.00047Clark, D. P., & Badea, C. T. (2014). Micro-CT of rodents: State-of-the-art and future perspectives. Physica Medica, 30(6), 619-634. doi:10.1016/j.ejmp.2014.05.011Drzezga, A., Souvatzoglou, M., Eiber, M., Beer, A. J., Fürst, S., Martinez-Möller, A., … Schwaiger, M. (2012). First Clinical Experience with Integrated Whole-Body PET/MR: Comparison to PET/CT in Patients with Oncologic Diagnoses. Journal of Nuclear Medicine, 53(6), 845-855. doi:10.2967/jnumed.111.098608Gonzalez, A. J., Aguilar, A., Conde, P., Hernandez, L., Moliner, L., Vidal, L. F., … Benlloch, J. M. (2016). A PET Design Based on SiPM and Monolithic LYSO Crystals: Performance Evaluation. IEEE Transactions on Nuclear Science, 63(5), 2471-2477. doi:10.1109/tns.2016.2522179Gonzalez, A. J., Pincay, E. J., Canizares, G., Lamprou, E., Sanchez, S., Catret, J. V., … Correcher, C. (2019). Initial Results of the MINDView PET Insert Inside the 3T mMR. IEEE Transactions on Radiation and Plasma Medical Sciences, 3(3), 343-351. doi:10.1109/trpms.2018.2866899Grant, A. M., Lee, B. J., Chang, C.-M., & Levin, C. S. (2017). Simultaneous PET/MR imaging with a radio frequency-penetrable PET insert. Medical Physics, 44(1), 112-120. doi:10.1002/mp.12031Habte, F., Ren, G., Doyle, T. C., Liu, H., Cheng, Z., & Paik, D. S. (2013). Impact of a Multiple Mice Holder on Quantitation of High-Throughput MicroPET Imaging With and Without Ct Attenuation Correction. Molecular Imaging and Biology, 15(5), 569-575. doi:10.1007/s11307-012-0602-yHammer, B. E., Christensen, N. L., & Heil, B. G. (1994). Use of a magnetic field to increase the spatial resolution of positron emission tomography. Medical Physics, 21(12), 1917-1920. doi:10.1118/1.597178Jadvar, H., & Colletti, P. M. (2014). Competitive advantage of PET/MRI. European Journal of Radiology, 83(1), 84-94. doi:10.1016/j.ejrad.2013.05.028Judenhofer, M. S., Catana, C., Swann, B. K., Siegel, S. B., Jung, W.-I., Nutt, R. E., … Pichler, B. J. (2007). PET/MR Images Acquired with a Compact MR-compatible PET Detector in a 7-T Magnet. Radiology, 244(3), 807-814. doi:10.1148/radiol.2443061756Kinahan, P. E., Townsend, D. W., Beyer, T., & Sashin, D. (1998). Attenuation correction for a combined 3D PET/CT scanner. Medical Physics, 25(10), 2046-2053. doi:10.1118/1.598392Ko, G. B., Yoon, H. S., Kim, K. Y., Lee, M. S., Yang, B. Y., Jeong, J. M., … Lee, J. S. (2016). Simultaneous Multiparametric PET/MRI with Silicon Photomultiplier PET and Ultra-High-Field MRI for Small-Animal Imaging. Journal of Nuclear Medicine, 57(8), 1309-1315. doi:10.2967/jnumed.115.170019Lee, B. J., Grant, A. M., Chang, C.-M., Watkins, R. D., Glover, G. H., & Levin, C. S. (2018). MR Performance in the Presence of a Radio Frequency-Penetrable Positron Emission Tomography (PET) Insert for Simultaneous PET/MRI. IEEE Transactions on Medical Imaging, 37(9), 2060-2069. doi:10.1109/tmi.2018.2815620Loening, A. M., & Gambhir, S. S. (2003). AMIDE: A Free Software Tool for Multimodality Medical Image Analysis. Molecular Imaging, 2(3), 131-137. doi:10.1162/153535003322556877Mannheim, J. G., Schmid, A. M., Schwenck, J., Katiyar, P., Herfert, K., Pichler, B. J., & Disselhorst, J. A. (2018). PET/MRI Hybrid Systems. Seminars in Nuclear Medicine, 48(4), 332-347. doi:10.1053/j.semnuclmed.2018.02.011Maramraju, S. H., Smith, S. D., Junnarkar, S. S., Schulz, D., Stoll, S., Ravindranath, B., … Schlyer, D. J. (2011). Small animal simultaneous PET/MRI: initial experiences in a 9.4 T microMRI. Physics in Medicine and Biology, 56(8), 2459-2480. doi:10.1088/0031-9155/56/8/009Molinos, C., Sasser, T., Salmon, P., Gsell, W., Viertl, D., Massey, J. C., … Heidenreich, M. (2019). Low-Dose Imaging in a New Preclinical Total-Body PET/CT Scanner. Frontiers in Medicine, 6. doi:10.3389/fmed.2019.00088Nagy, K., Tóth, M., Major, P., Patay, G., Egri, G., Häggkvist, J., … Gulyás, B. (2013). Performance Evaluation of the Small-Animal nanoScan PET/MRI System. Journal of Nuclear Medicine, 54(10), 1825-1832. doi:10.2967/jnumed.112.119065Nanni, C., & Torigian, D. A. (2008). Applications of Small Animal Imaging with PET, PET/CT, and PET/MR Imaging. PET Clinics, 3(3), 243-250. doi:10.1016/j.cpet.2009.01.002Omidvari, N., Cabello, J., Topping, G., Schneider, F. R., Paul, S., Schwaiger, M., & Ziegler, S. I. (2017). PET performance evaluation of MADPET4: a small animal PET insert for a 7 T MRI scanner. Physics in Medicine & Biology, 62(22), 8671-8692. doi:10.1088/1361-6560/aa910dOmidvari, N., Topping, G., Cabello, J., Paul, S., Schwaiger, M., & Ziegler, S. I. (2018). MR-compatibility assessment of MADPET4: a study of interferences between an SiPM-based PET insert and a 7 T MRI system. Physics in Medicine & Biology, 63(9), 095002. doi:10.1088/1361-6560/aab9d1Raylman, R. R., Majewski, S., Lemieux, S. K., Velan, S. S., Kross, B., Popov, V., … Marano, G. D. (2006). Simultaneous MRI and PET imaging of a rat brain. Physics in Medicine and Biology, 51(24), 6371-6379. doi:10.1088/0031-9155/51/24/006Roncali, E., & Cherry, S. R. (2011). Application of Silicon Photomultipliers to Positron Emission Tomography. Annals of Biomedical Engineering, 39(4), 1358-1377. doi:10.1007/s10439-011-0266-9Schug, D., Lerche, C., Weissler, B., Gebhardt, P., Goldschmidt, B., Wehner, J., … Schulz, V. (2016). Initial PET performance evaluation of a preclinical insert for PET/MRI with digital SiPM technology. Physics in Medicine and Biology, 61(7), 2851-2878. doi:10.1088/0031-9155/61/7/2851Shao, Y., Cherry, S. R., Farahani, K., Meadors, K., Siegel, S., Silverman, R. W., & Marsden, P. K. (1997). Simultaneous PET and MR imaging. Physics in Medicine and Biology, 42(10), 1965-1970. doi:10.1088/0031-9155/42/10/010Steinert, H. C., & von Schulthess, G. K. (2002). Initial clinical experience using a new integrated in-line PET/CT system. The British Journal of Radiology, 75(suppl_9), S36-S38. doi:10.1259/bjr.75.suppl_9.750036Stortz, G., Thiessen, J. D., Bishop, D., Khan, M. S., Kozlowski, P., Retière, F., … Sossi, V. (2017). Performance of a PET Insert for High-Resolution Small-Animal PET/MRI at 7 Tesla. Journal of Nuclear Medicine, 59(3), 536-542. doi:10.2967/jnumed.116.187666Townsend, D. W. (2008). Combined Positron Emission Tomography–Computed Tomography: The Historical Perspective. Seminars in Ultrasound, CT and MRI, 29(4), 232-235. doi:10.1053/j.sult.2008.05.006Vandenberghe, S., & Marsden, P. K. (2015). PET-MRI: a review of challenges and solutions in the development of integrated multimodality imaging. Physics in Medicine and Biology, 60(4), R115-R154. doi:10.1088/0031-9155/60/4/r115Vaquero, J. J., & Kinahan, P. (2015). Positron Emission Tomography: Current Challenges and Opportunities for Technological Advances in Clinical and Preclinical Imaging Systems. Annual Review of Biomedical Engineering, 17(1), 385-414. doi:10.1146/annurev-bioeng-071114-040723Von Schulthess, G. K., & Schlemmer, H.-P. W. (2008). A look ahead: PET/MR versus PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 36(S1), 3-9. doi:10.1007/s00259-008-0940-9Wehner, J., Weissler, B., Dueppenbecker, P. M., Gebhardt, P., Goldschmidt, B., Schug, D., … Schulz, V. (2015). MR-compatibility assessment of the first preclinical PET-MRI insert equipped with digital silicon photomultipliers. Physics in Medicine and Biology, 60(6), 2231-2255. doi:10.1088/0031-9155/60/6/2231Wehrl, H. F., Judenhofer, M. S., Thielscher, A., Martirosian, P., Schick, F., & Pichler, B. J. (2010). Assessment of MR compatibility of a PET insert developed for simultaneous multiparametric PET/MR imaging on an animal system operating at 7 T. Magnetic Resonance in Medicine, 65(1), 269-279. doi:10.1002/mrm.22591Yamamoto, S., Imaizumi, M., Kanai, Y., Tatsumi, M., Aoki, M., Sugiyama, E., … Hatazawa, J. (2010). Design and performance from an integrated PET/MRI system for small animals. Annals of Nuclear Medicine, 24(2), 89-98. doi:10.1007/s12149-009-0333-6Yamamoto, S., Watabe, T., Watabe, H., Aoki, M., Sugiyama, E., Imaizumi, M., … Hatazawa, J. (2011). Simultaneous imaging using Si-PM-based PET and MRI for development of an integrated PET/MRI system. Physics in Medicine and Biology, 57(2), N1-N13. doi:10.1088/0031-9155/57/2/n1Zaidi, H., Montandon, M.-L., & Alavi, A. (2008). The Clinical Role of Fusion Imaging Using PET, CT, and MR Imaging. PET Clinics, 3(3), 275-291. doi:10.1016/j.cpet.2009.03.00

Thermal study of the effect of several solvents on polymerization of acrylonitrile and their subsequent pyrolysis

The polymerization of acrylonitrile to polyacrylonitrile (PAN) has been studied using several solvents: N,N-dimethylformamide (DMF), hexane, toluene, water, and in bulk form (no solvent). The addition of DMF is the only case where both monomer and polymer are soluble in the solvent. Thermal analyses of the resultant products after polymerization have been performed by differential scanning calorimetry and pyrolysis–gas chromatography: mass spectrometry. The effect of the solvents employed as media for polymerization is interpreted from the results of the thermal and structural (X-ray diffraction) methods. The polymer samples obtained when using water or toluene as solvents have the greater content of amorphous components compared to the others. The amide molecules are difficult to completely eliminate in the product obtained after the polymerization reaction and even after prolonged heating at 110°C and remain occluded. DMF can be considered to exert a plasticized effect on PAN and is even capable of forming complexes by dipolar bonding. As a result of this interaction, the thermogram is quite different from the other samples studied in the present work, showing a single sharp exothermic peak. This is associated with nitrile group polymerization (cyclization) of PAN. It is deduced that the amount of heat evolved as well as the temperature interval over which it is released are influenced by the chemical processing of PAN, in particular when using DMF as solvent for both monomer and polymer. Pyrolysis of the different PAN samples revealed the release of occluded solvent molecules, mainly when using DMF, and compounds produced from the thermal degradation processes. Different types of cyclized compounds, such as pyridine derivatives and aromatic nitriles were identified. All these compounds could be derived from cyclized PAN structures which are not completely degraded by the thermal treatment of pyrolysis. Alkyldinitriles have also been tentatively identified associated with the final molecular breakdown of cyclized structures with six-member rings by pyrolysis. Valuable complementary information on the structure of the PAN samples (homopolymer) obtained using the different processing approaches involving several solvent media has been provided by pyrolysis. The present results will improve our understanding of the evolution of the structure and properties of carbon and activated carbon fibres which will enable us to establish processing strategies in order to obtain these materials under adequate and reproducible conditions.Peer reviewe

MicroRNAs promote skeletal muscle differentiation of mesodermal iPSC-derived progenitors

Muscular dystrophies (MDs) are often characterized by impairment of both skeletal and cardiac muscle. Regenerative strategies for both compartments therefore constitute a therapeutic avenue. Mesodermal iPSC-derived progenitors (MiPs) can regenerate both striated muscle types simultaneously in mice. Importantly, MiP myogenic propensity is influenced by somatic lineage retention. However, it is still unknown whether human MiPs have in vivo potential. Furthermore, methods to enhance the intrinsic myogenic properties of MiPs are likely needed, given the scope and need to correct large amounts of muscle in the MDs. Here, we document that human MiPs can successfully engraft into the skeletal muscle and hearts of dystrophic mice. Utilizing non-invasive live imaging and selectively induced apoptosis, we report evidence of striated muscle regeneration in vivo in mice by human MiPs. Finally, combining RNA-seq and miRNA-seq data, we define miRNA cocktails that promote the myogenic potential of human MiPs

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Oligometastatic disease represents a clinical and anatomical manifestation between localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition of oligometastatic disease enables focal, metastasisdirected therapies. These therapies potentially shorten or postpone the use of systemic treatment and can delay further metastatic progression, thus increasing overall survival. Metastasis-directed therapies require imaging methods that definitively recognise oligometastatic disease to validate their efficacy and reliably monitor response, particularly so that morbidity associated with inappropriately treating disease subsequently recognised as polymetastatic can be avoided. In this Review, we assess imaging methods used to identify metastatic prostate cancer at first diagnosis, at biochemical recurrence, or at the castration-resistant stage. Standard imaging methods recommended by guidelines have insufficient diagnostic accuracy for reliably diagnosing oligometastatic disease. Modern imaging methods that use PET-CT with tumour-specific radiotracers (choline or prostate-specific membrane antigen ligand), and increasingly whole-body MRI with diffusion-weighted imaging, allow earlier and more precise identification of metastases. The European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group suggests clinical algorithms to integrate modern imaging methods into the care pathway at the various stages of prostate cancer to identify oligometastatic disease. The EORTC proposes clinical trials that use modern imaging methods to evaluate the benefits of metastasis-directed therapies

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

Purpose: To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate. Methods: In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results: Significantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low ( 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions: 177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov : NCT01578239, EudraCT: 2011-005049-11

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

Purpose: To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate. Methods: In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression. Results: Significantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low ( 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden. Conclusions: 177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov: NCT01578239, EudraCT: 2011-005049-11

Imaging standardization in metastatic colorectal cancer : a joint EORTC-ESOI-ESGAR expert consensus recommendation

Background: Treatment monitoring in metastatic colorectal cancer (mCRC) relies on imaging to evaluate the tumor burden. Response Evaluation Criteria in Solid Tumors (RECIST) provide a framework on reporting and interpretation of imaging findings yet offer no guidance on a standardized imaging protocol tailored to mCRC patients. Imaging protocol heterogeneity remains a challenge for the reproducibility of conventional imaging endpoints and is an obstacle for research on novel imaging endpoints. Patients and methods: Acknowledging the recently highlighted potential of radiomics and artificial intelligence (AI) tools as decision support for patient care in mCRC, a multidisciplinary, international, and expert panel of imaging specialists was formed to find consensus on mCRC imaging protocols using the Delphi method. Results: Under the guidance of the European Organisation for Research and Treatment of Cancer (EORTC) Imaging and Gastrointestinal Tract Cancer Groups, the European Society of Oncologic Imaging (ESOI) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), the EORTC-ESOI-ESGAR core imaging protocol was identified. Conclusion: This consensus protocol attempts to promote standardization and to diminish variations in patient preparation, scan acquisition and scan reconstruction. We anticipate that this standardization will increase reproducibility of radiomics and AI studies and serve as a catalyst for future research on imaging endpoints. For ongoing and future mCRC trials, we encourage principal investigators to support the dissemination of these imaging standards across recruiting centers.peer-reviewe